PANews, December 2nd news, according to market news, the NASDAQ-listed biotech company Sonnet BioTherapeutics has received shareholder approval to merge with Hyperliquid Strategies, Inc.
According to previous news, the listed company Sonnet plans to change its name to Hyperliquid Strategies through a merger transaction, and it is expected to hold 12.6 million HYPE and 300 million dollars in cash.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sonnet BioTherapeutics has received shareholder approval to merge with Hyperliquid Strategies, Inc.
PANews, December 2nd news, according to market news, the NASDAQ-listed biotech company Sonnet BioTherapeutics has received shareholder approval to merge with Hyperliquid Strategies, Inc. According to previous news, the listed company Sonnet plans to change its name to Hyperliquid Strategies through a merger transaction, and it is expected to hold 12.6 million HYPE and 300 million dollars in cash.